Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Reports summarize cancer gene therapy research from Cancer Research Center
February 24th, 2009
Researchers detail in 'Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect,' new data in cancer gene therapy. According to a study from Madrid, Spain, "Sirtuin 1 (Sirt1) and Sirtuin 2 (Sirt2) belong to the family of NAD+ (nicotinamide adenine dinucleotide-positive)-dependent class III histone deacetylases and are involved in regulating lifespan. As cancer is a disease of aging, targeting Sirtuins is emerging as a promising antitumour strategy." "Here we present Salermide (N-{3-[(2-hydroxy-naphthalen-1-ylmethylene)-amino]-phenyl}-2-phenyl-propionamide), a reverse amide with a strong in vitro inhibitory effect on Sirt1 and Sirt2. Salermide was...
Source: Cancer Weekly (2009-02-24)
|
